Navigation Links
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Date:10/15/2007

een approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc.

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led by Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS-760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Knopp Neurosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
5. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
6. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Point of Care Strep Tests Speed Treatment, Lower Costs
10. Rapid HIV Testing Increases Possibility of Treatment
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... Morris , chief financial officer  will be participating in ... as follows: Mizuho Third Annual Healthcare Corporate ... Berkshire Place, New York ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
(Date:4/30/2015)... April 30, 2015   Regulus Therapeutics Inc . ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended March 31, 2015 on Thursday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its first quarter ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... April 14, 2011 Transgenomic, Inc. (OTC/BB: TBIO) announced ... of the BRAF and PIK3CA genes. These ... K-RAS , expanding Transgenomic,s range of its proprietary SURVEYOR Scan ... K-RAS , BRAF , and PIK3CA ) are widely ...
... Nev., April 14, 2011 Sanare, LLC, a ... with diabetes, announced today the launch of its ... BrightSky is the backbone of Sanare,s ... health plans. The offering includes personalized access to ...
Cached Medicine Technology:Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 2Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 3Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits 4Sanare Launches BrightSky, a New Consumer Brand Serving People Living With Diabetes 2
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... May 02, 2015 “ ActOn ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... get connected with organizations to make a difference. , In ... very few things that aren’t about money, which is why ...
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
Breaking Medicine News(10 mins):Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4
... When you check into a hospital, the odds are one ... of antibiotic-resistant bacteria as a result of your stay. That ... todays hospitals despite the best efforts of the medical profession. ... deaths per year., Now, a sophisticated new mathematical model has ...
... for,Plastination commends ABC,s 20/20 for its investigation on ... exhibitions. The program served to,inform and educate the ... of bodies used in anatomical exhibitions in particular., ... clarify two vague,statements made by anatomist, Dr. Gunther ...
... survival rates to younger cases , , FRIDAY, Feb. 15 ... transplantation and have good outcomes, and age should not ... a new study says. , Researchers at the University ... of 48 UCLA patients between the ages of 65 ...
... Canadian scientists are finding that out of sight, out of ... the chemicals in our waters. Substances that we use everyday ... they can impact aquatic life and possibly ourselves. , ... of the 30,000 or so chemicals used commercially in the ...
... Premier Exhibitions Inc.,(Nasdaq: PRXI ) today posted ... to an expected 20/20 broadcast that is purported ... to its controversial and,highly successful bodies exhibitions., ... TV,s 20/20 has,chosen to air a segment that ...
... 15 IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced ... by the Company of an additional four million,shares of ... will be made in the open market or in ... shares remaining as of,December 31, 2007, under a previous ...
Cached Medicine News:Health News:Math model identifies key to controlling epidemic 2Health News:Math model identifies key to controlling epidemic 3Health News:Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program 2Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:New findings on emerging contaminants 2Health News:New findings on emerging contaminants 3Health News:New findings on emerging contaminants 4Health News:New findings on emerging contaminants 5Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 2Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 3
Straight shafts with 6 mm tying platform and crisscross serrated tips. Round knurled handle with polished finish. Overall length 4.5 inches....
Curved shafts and tips with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in closed position with polished finish. Overall length 4.3 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches....
5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
Medicine Products: